Goldman Sachs analyst Terrence Flynn downgraded Gilead from Neutral to Sell and lowered the price target from $70 to $60.
Gilead's topline is likely to decelerate in the near term, as the Truvada/Atripla loss of exclusivity in September 2020 represents a $3-billion headwind, Flynn said in a Tuesday downgrade note.
In the long-term, the analyst expects Biktarvy to protect only half of the company's $16-billion HIV franchise from generic competition.
Flynn said he estimates a revenue CAGR of negative 5 percent for the 2019-2022 period, the lowest in his coverage universe, even as Gilead stock is trading at a slight premium to peers such as Bristol-Myers Squibb Co (NYSE: BMY) and AbbVie Inc (NYSE: ABBV).
Bristol-Myers And AbbVie — though holding the same upcoming loss of exclusivity exposure as Gilead — have new product cycles and/or pipelines that offer optionality, the analyst said.
Gilead will only have one year to market Descovy for PrEP ahead of the entry of Truvada generic in September 2020, he said.
Gilead has a very limited mid-to-late stage pipeline, Flynn said.
Goldman reduced its estimates for the immunology drug Filgotinib, citing competition and recent data.
"GILD currently trades at ~10x NTM P/E and barring another "Pharmasset" and/or internal pipeline success we find it difficult to see the stock's multiple expanding."
The Price Action
Gilead shares were sliding by 2.4 percent to $65.28 at the time of publication Tuesday.
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
WSJ: MiMedx Injectables Flout FDA Regulations
Latest Ratings for GILD
|May 2019||Initiates Coverage On||Neutral|
View More Analyst Ratings for GILD
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
- What's The Buzz Around Novartis' Gene Therapy Zolgensma?
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.